Jon Napitupulu

Nurix Therapeutics will step onto the investor stage in November, with its president and CEO slated for fireside chats...

Amneal Pharmaceuticals posted third-quarter 2025 revenue of $785 million, up 12% year over year, and nudged its full-year outlook...

NovaBridge’s ophthalmology subsidiary, Visara, has assigned its exclusive license for VIS-101 to Everest Medicines for development, manufacturing, and commercialization...

Cytek Biosciences has launched a two-part initiative with the International Society for Advancement of Cytometry to widen access to...

BridgeBio reported third-quarter revenue of $120.7 million, fueled by $108.1 million in U.S. net product sales of Attruby (acoramidis)...

Roche has secured control of 89bio through a completed tender offer at 14.50 dollars per share in cash plus...

Argenx reported a pivotal third quarter: $1.13 billion in global net product sales, driven by the Vyvgart franchise across...

Cytek Biosciences has launched a two-part initiative with the International Society for Advancement of Cytometry to expand access to...

BridgeBio reported third-quarter revenue of $120.7 million, anchored by $108.1 million in U.S. net product sales from Attruby (acoramidis)...

Argenx presented a sweep of new Vyvgart data at AANEM/MGFA 2025, headlined by the phase 3 ADAPT SERON trial...